Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will ...

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.27%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.36, delivering a surprise of -5.88%.Over the last four quarters, the company has sur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-38148 CO-DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results SALT LAKE CITY, May 8, 2025— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results: First Quarter Business Highlights: "During the quarter, Co-Diagnostics continued to make significant progress in the development of our test ...

SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first qu ...

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, ...

Core Viewpoint - Co-Diagnostics, Inc. (CODX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that upward revisions in earnings estimates can lead to higher stock valuations [4][6]. - CoDiagnostics is expected to earn -$0.91 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 26.6% [8]. Analyst Sentiment and Market Position - Analysts have increased their earnings estimates for CoDiagnostics, with the Zacks Consensus Estimate rising by 22.2% over the past three months [8]. - The upgrade to Zacks Rank 2 places CoDiagnostics in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Company Performance - Co-Diagnostics, Inc. reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, but an improvement from a loss of $0.50 per share a year ago, indicating a year-over-year improvement in loss figures [1] - The company posted revenues of $0.15 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 60.79%, and a significant decline from year-ago revenues of $3.56 million [2] - Over the last four quarters, Co-Diagnostics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Co-Diagnostics shares have declined approximately 44.5% since the beginning of the year, contrasting with the S&P 500's decline of 2.9%, indicating significant underperformance in the market [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $0.4 million, and for the current fiscal year, it is -$1.17 on revenues of $1.5 million [7] Industry Outlook - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a relatively strong position within the market [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Co-Diagnostics' stock performance [5]

Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, that this event ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION CO-DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______to_______ Commission File Number 001-38148 (I.R.S. Employer Identification Numbe ...